Audit MicroControls Linearity FD Tumor Markers II
Multi-Analyte Controls, All Kinds (Assayed). 510(k) K143573, from Aalto Scientific, Ltd. (Carlsbad, CA). Product code JJY, class 1.
As of Nov 20, 2026, K143573 is an FDA 510(k) held by Aalto Scientific, Ltd., substantially equivalent on Jan 16, 2015 after 30 days, with no recalls tied to it in FDA's recall database.
- Review time: 30 days
- Recalls: 0
The Linearity FD Tumor Markers II is an assayed quality control material intended to simulate human patient samples for use in determining linearity, calibration verification, and the verification of reportable range for the following analytes: Alpha fetoprotein (AFP), Carcinoembryonic antigen (CEA), Prostate-specific antigen-total (PSA), Carbonic Anhydrase-125 (CA-125), Carbonic Anhydrase 19-9…
- Audit Microcv Tumor Markers Linearity Set, Model K719M-5K082717 · Aalto Scientific, Ltd. · Oct 30, 2008
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Dec 17, 2014
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1660
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files